Type 2 diabetes mellitus (T2DM) is a polygenic metabolic disorder characterized by hyperglycemia occurring as a result of impaired insulin secretion and/or insulin resistance. Among the various genetic factors associated with T2DM, a common genetic variant within the transcription factor 7-like 2 locus (TCF7L2) confers the greatest genetic risk for development of the disease. However, the mechanism(s) by which TCF7L2 predisposes to diabetes remain uncertain. Here we review the current literature pertaining to the potential mechanisms by which TCF7L2 confers risk of T2DM, using genetic variation as a probe to understand the pathogenesis of the disease.
Get full access to this article
View all access options for this article.
References
1.
AlbrightAL, GreggEW. Preventing type 2 diabetes in communities across the U.S.: The National Diabetes Prevention Program. Am J Prev Med, 2013; 44(4 Suppl 4):S346–S351.
2.
BergmanRN, PhillipsLS, CobelliC. Physiologic evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest, 1981; 68:1456–1467.
3.
ShahP, BasuA, BasuR, et al.Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol, 1999; 277(2 Pt 1):E283–E290.
4.
ShahP, VellaA, BasuA, et al.Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab, 2000; 85:4053–4059.
5.
DoriaA, PattiME, KahnCR. The emerging genetic architecture of type 2 diabetes. Cell Metab, 2008; 8:186–200.
6.
FlorezJC, HirschhornJ, AltshulerD. The inherited basis of diabetes mellitus: Implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet, 2003; 4:257–291.
7.
TalmudPJ, CooperJA, MorrisRW, et al.Sixty-five common genetic variants and prediction of type 2 diabetes. Diabetes, 2015; 64:1830–1840.
8.
MoltkeI, GrarupN, JorgensenME, et al.A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature, 2014; 512:190–193.
9.
FuchsbergerC, FlannickJ, TeslovichTM, et al.The genetic architecture of type 2 diabetes. Nature, 2016; 536:41–47.
10.
MeigsJB, ShraderP, SullivanLM, et al.Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med, 2008; 359:2208–2219.
11.
PearsonER, DonnellyLA, KimberC, et al.Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes, 2007; 56:2178–2182.
12.
ShahM, VargheseRT, MilesJM, et al.TCF7L2 genotype and alpha-cell function in humans without diabetes. Diabetes, 2016; 65:371–380.
13.
FlorezJC, JablonskiKA, BayleyN, et al.TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med, 2006; 355:241–250.
14.
DuggiralaR, BlangeroJ, AlmasyL, et al.Linkage of type 2 diabetes mellitus and of age at onset to a genetic location on chromosome 10q in Mexican Americans. Am J Hum Genet, 1999; 64:1127–1140.
15.
ReynisdottirI, ThorleifssonG, BenediktssonR, et al.Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34–q35.2. Am J Hum Genet, 2003; 73:323–335.
16.
GrantSF, ThorleifssonG, ReynisdottirI, et al.Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet, 2006; 38:320–323.
17.
PalmerND, HesterJM, AnSS, et al.Resequencing and analysis of variation in the TCF7L2 gene in African Americans suggests that SNP rs7903146 is the causal diabetes susceptibility variant. Diabetes, 2011; 60:662–668.
18.
Wellcome Trust Case ControlC, MallerJB, McVeanG, et al.Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet, 2012; 44:1294–1301.
19.
GaultonKJ, NammoT, PasqualiL, et al.A map of open chromatin in human pancreatic islets. Nat Genet, 2010; 42:255–259.
20.
HayashiT, IwamotoY, KakuK, et al.Replication study for the association of TCF7L2 with susceptibility to type 2 diabetes in a Japanese population. Diabetologia, 2007; 50:980–984.
21.
MiyakeK, HorikawaY, HaraK, et al.Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4,087 Japanese subjects. J Hum Genet, 2008; 53:174–180.
22.
GuoT, HansonRL, TraurigM, et al.TCF7L2 is not a major susceptibility gene for type 2 diabetes in Pima Indians: Analysis of 3,501 individuals. Diabetes, 2007; 56:3082–3088.
23.
ElbeinSC, ChuWS, DasSK, et al.Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. Diabetologia, 2007; 50:1621–1630.
24.
Huertas-VazquezA, PlaisierC, Weissglas-VolkovD, et al.TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. Diabetologia, 2008; 51:62–69.
25.
JinT.Current understanding on role of the Wnt signaling pathway effector TCF7L2 in glucose homeostasis. Endocr Rev, 2016; 37:254–277.
26.
XiaQ, ChesiA, ManduchiE, et al.The type 2 diabetes presumed causal variant within TCF7L2 resides in an element that controls the expression of ACSL5. Diabetologia, 2016; 59:2360–2368.
27.
BowmanTA, O'KeeffeKR, D'AquilaT, et al.Acyl CoA synthetase 5 (ACSL5) ablation in mice increases energy expenditure and insulin sensitivity and delays fat absorption. Mol Metab, 2016; 5:210–220.
28.
CervinC, LyssenkoV, BakhtadzeE, et al.Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes, 2008; 57:1433–1437.
29.
da Silva XavierG, MondragonA, SunG, et al.Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice. Diabetologia, 2012; 55:2667–2676.
30.
da Silva XavierG, MondragonA, MourougavelouV, et al.Pancreatic alpha cell-selective deletion of Tcf7l2 impairs glucagon secretion and counter-regulatory responses to hypoglycaemia in mice. Diabetologia, 2017; 60:1043–1050.
31.
LyssenkoV, LupiR, MarchettiP, et al.Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest, 2007; 117:2155–2163.
32.
KorinekV, BarkerN, MoererP, et al.Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet, 1998; 19:379–383.
33.
YangH, LiQ, LeeJH, et al.Reduction in Tcf7l2 expression decreases diabetic susceptibility in mice. Int J Biol Sci, 2012; 8:791–801.
34.
SavicD, YeH, AneasI, et al.Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism. Genome Res, 2011; 21:1417–1425.
35.
BojSF, van EsJH, HuchM, et al.Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell, 2012; 151:1595–1607.
36.
MitchellRK, MondragonA, ChenL, et al.Selective disruption of Tcf7l2 in the pancreatic beta cell impairs secretory function and lowers beta cell mass. Hum Mol Genet, 2015; 24:1390–1399.
37.
SakhnenyL, RachiE, EpshteinA, et al.Pancreatic pericytes support beta-cell function in a Tcf7l2-dependent manner. Diabetes, 2018; 67:437–447.
38.
BaileyKA, SavicD, ZielinskiM, et al.Evidence of non-pancreatic beta cell-dependent roles of Tcf7l2 in the regulation of glucose metabolism in mice. Hum Mol Genet, 2015; 24:1646–1654.
39.
NiZ, AniniY, FangX, et al.Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J Biol Chem, 2003; 278:1380–1387.
40.
YiF, BrubakerPL, JinT. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem, 2005; 280:1457–1464.
41.
HabenerJF, LiuZ.Wnt signaling in pancreatic islets. In: IslamM (ed). Islets of Langerhans, 2nd ed., Dordrecht: Springer; 2014:1–31.
42.
JinT, LiuL. The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol, 2008; 22:2383–2392.
43.
MurtaughLC, LawAC, DorY, et al.Beta-catenin is essential for pancreatic acinar but not islet development. Development, 2005; 132:4663–4674.
44.
PapadopoulouS, EdlundH. Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes, 2005; 54:2844–2851.
45.
RulifsonIC, KarnikSK, HeiserPW, et al.Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A, 2007; 104:6247–6252.
46.
RossSE, HematiN, LongoKA, et al.Inhibition of adipogenesis by Wnt signaling. Science, 2000; 289:950–953.
47.
SathananthanA, Dalla ManC, ZinsmeisterAR, et al.A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. Clin Endocrinol (Oxf), 2012; 76:212–219.
48.
MeierJJ, VeldhuisJD, ButlerPC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes, 2005; 54:1649–1656.
49.
CobelliC, Dalla ManC, ToffoloG, et al.The oral minimal model method. Diabetes, 2014; 63:1203–1213.
50.
BockG, ChittilapillyE, BasuR, et al.Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: Role of increased rates of gluconeogenesis. Diabetes, 2007; 56:1703–1711.
51.
TonelliJ, KishoreP, LeeDE, et al.The regulation of glucose effectiveness: How glucose modulates its own production. Curr Opin Clin Nutr Metab Care, 2005; 8:450–456.
52.
AvogaroA, ViciniP, ValerioA, et al.The hot but not the cold minimal model allows precise assessment of insulin sensitivity in NIDDM subjects. Am J Physiol, 1996; 270(3 Pt 1):E532–E540.
53.
DamcottCM, PollinTI, ReinhartLJ, et al.Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: Replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes, 2006; 55:2654–2659.
54.
MunozJ, LokKH, GowerBA, et al.Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes, 2006; 55:3630–3634.
55.
PalmerND, LehtinenAB, LangefeldCD, et al.Association of TCF7L2 gene polymorphisms with reduced acute insulin response in Hispanic Americans. J Clin Endocrinol Metab, 2008; 93:304–309.
56.
WegnerL, HussainMS, PilgaardK, et al.Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins. J Clin Endocrinol Metab, 2008; 93:4013–4019.
57.
SchaferSA, TschritterO, MachicaoF, et al.Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia, 2007; 50:2443–2450.
58.
SmushkinG, SathananthanM, SathananthanA, et al.Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes, 2012; 61:1082–1089.
59.
DanieleG, GagginiM, ComassiM, et al.Glucose metabolism in high-risk subjects for type 2 diabetes carrying the rs7903146 TCF7L2 gene variant. J Clin Endocrinol Metab, 2015; 100:E1160–E1167.
60.
GjesingAP, KjemsLL, VestmarMA, et al.Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test. Diabetologia, 2011; 54:103–110.
61.
SilbernagelG, RennerW, GrammerTB, et al.Association of TCF7L2 SNPs with age at onset of type 2 diabetes and proinsulin/insulin ratio but not with glucagon-like peptide 1. Diabetes Metab Res Rev, 2011; 27:499–505.
62.
PilgaardK, JensenCB, SchouJH, et al.The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia, 2009; 52:1298–1307.
63.
Rasmussen-TorvikLJ, PankowJS, JacobsDRJr., et al.Preliminary report: No association between TCF7L2 rs7903146 and euglycemic-clamp-derived insulin sensitivity in a mixed-age cohort. Metabolism, 2009; 58:1369–1371.
64.
MulhollandDJ, DedharS, CoetzeeGA, et al.Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?. Endocr Rev, 2005; 26:898–915.
65.
VargheseRT, ViegasI, BarosaC, et al.Diabetes-associated variation in TCF7L2 is not associated with hepatic or extrahepatic insulin resistance. Diabetes, 2016; 65:887–892.
66.
Vazquez-RoqueMI, CamilleriM, VellaA, et al.Association of TCF7L2 allelic variations with gastric function, satiation, and GLP-1 levels. Clin Transl Sci, 2011; 4:183–187.
67.
Le BacquerO, Kerr-ConteJ, GarganiS, et al.TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals. Diabetologia, 2012; 55:2677–2681.
68.
IngelssonE, LangenbergC, HivertMF, et al.Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes, 2010; 59:1266–1275.
